Clinical Trial Update: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations [Phase 3]

View source ↗

Summary

Phase 3 study comparing Datopotamab Deruxtecan to Docetaxel in previously treated, TROP2-positive advanced or metastatic non-squamous non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Datopotamab Deruxtecan (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING